Guggulsterone, a farnesoid X receptor antagonist lowers plasma trimethylamine-N-oxide levels: An evidence from in vitro and in vivo studies

• Published in: Human & experimental toxicology 2019-03, Vol.38 (3), p.356-370
• Main Authors: Gautam, A, Paudel, YN, Abidin, SAZ, Bhandari, U
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Antioxidants; Antioxidants - pharmacology; Aorta; Arteriosclerosis; Atherosclerosis; Atherosclerosis - metabolism; Atherosclerosis - pathology; Attenuation; Biomarkers; Cardiotonic Agents - pharmacology; Cholesterol; Choline; Choline - pharmacology; Chromatography; Clostridium - metabolism; Cytokines; Density; Diet; Escherichia - metabolism; Flavin; High performance liquid chromatography; Hypolipidemic Agents - pharmacology; In vivo methods and tests; Inflammation; Injury prevention; Kidney - drug effects; Kidney - metabolism; Lipid peroxidation; Lipid Peroxidation - drug effects; Lipids; Lipoproteins; Liquid chromatography; Liver - drug effects; Liver - metabolism; Mass spectroscopy; Metabolism; Methylamines - blood; Methylamines - metabolism; Myocardium - metabolism; Myocardium - pathology; Oxidative stress; Performance indices; Peroxidation; Pregnenediones - pharmacology; Rats, Wistar; Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors; Rodents; Triglycerides; Trimethylamine; Trimethylamine-N-oxide
• ISSN: 0960-3271; 1477-0903
• DOI: 10.1177/0960327118817862

The current study investigated the role of guggulsterone (GS), a farnesoid X receptor antagonist, in the choline metabolism and its trimethylamine (TMA)/flavin monooxygenases/trimethylamine-N-oxide (TMAO) inhibiting potential in a series of in vitro and in vivo studies as determined by high-performance liquid chromatography (HPLC), mass spectroscopy (MS), and liquid chromatography (LC)-MS techniques. Atherosclerosis (AS) was successfully induced in a group of experimental animals fed with 2% choline diet for 6 weeks. Serum lipid profiles such as total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and very low-density lipoprotein cholesterol were measured. Pro-inflammatory cytokines levels, markers for a hepatic injury, and oxidative stress markers were assessed. Interestingly, GS reduced the level of TMA/TMAO in both in vitro and in vivo studies as demonstrated by the peaks obtained from HPLC, MS, and LC–MS. Furthermore, GS exhibited cardioprotective and antihyperlipidemic effects as evidenced by the attenuation of levels of several serum lipid profiles and different atherogenic risk predictor indexes. GS also prevented hepatic injury by successfully restoring the levels of hepatic injury biomarkers to normal. Similarly, GS inhibited the production of pro-inflammatory cytokines levels, as well as GS, enhanced antioxidant capacity, and reduced lipid peroxidation. Histopathological study of aortic sections demonstrated that GS maintained the normal architecture in AS-induced rats. On the basis of results obtained from current investigation, we suggest that GS might have a great therapeutic potential for the treatment of AS.